Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

Conclusions
A statistically significant therapeutic effect of anrukinzumab could not be demonstrated in patients with active UC in spite of binding of anrukinzumab to IL-13.

Trial registration number
ClinicalTrials.gov number NCT01284062.

Source: Gut - May 8, 2015 Category: Gastroenterology Authors: Reinisch, W., Panes, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., Hinz, M., Page, K., O'Toole, M., Moorehead, T. M., Zhu, H., Sun, Y., Cataldi, F. Tags: Inflammatory bowel disease Source Type: research